1. Aberrant regulation favours matriptase proteolysis in neoplastic B-cells that co-express HAI-2
- Author
-
Yi-Lin Chiu, Yi-Ying Wu, Robert B. Barndt, Yee Hui Yeo, Yu-Wen Lin, Hou-Ping Sytwo, Huan-Cheng Liu, Yuan Xu, Bailing Jia, Jehng-Kang Wang, Michael D. Johnson, and Chen-Yong Lin
- Subjects
matriptase ,protease inhibition ,hai-1 ,hai-2 ,b-cell lymphoma ,pericellular proteolytic activity ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Matriptase is ectopically expressed in neoplastic B-cells, in which matriptase activity is enhanced by negligible expression of its endogenous inhibitor, hepatocyte growth factor activator inhibitor (HAI)-1. HAI-1, however, is also involved in matriptase synthesis and intracellular trafficking. The lack of HAI-1 indicates that other related inhibitor, such as HAI-2, might be expressed. Here, we show that HAI-2 is commonly co-expressed in matriptase-expressing neoplastic B-cells. The level of active matriptase shed after induction of matriptase zymogen activation in 7 different neoplastic B-cells was next determined and characterised. Our data reveal that active matriptase can only be generated and shed by those cells able to activate matriptase and in a rough correlation with the levels of matriptase protein. While HAI-2 can potently inhibit matriptase, the levels of active matriptase are not proportionally suppressed in those cells with high HAI-2. Our survey suggests that matriptase proteolysis might aberrantly remain high in neoplastic B-cells regardless of the levels of HAI-2.
- Published
- 2019
- Full Text
- View/download PDF